A clinical review proposes an evidence-informed framework for managing progression after immune checkpoint blockade in MSI-H/dMMR metastatic CRC, noting that BRAF V600E is common but not an absolute predictor of immunotherapy failure. (Journal of Gastrointestinal Cancer)
Treatment Sequencing After Immunotherapy Progression in MSI-H/dMMR Disease
The CRC Digest